RxDoctor Payments Data

Dean Kelaita, MD

Family Medicine · San Andreas, CANPI 1750310496

Payments from drug & device makers

$403in general payments, 2019–2025

Across 18 payments — averaging $22.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$123
  • Amgen$78
  • Johnson & Johnson$58
  • Pfizer$51
  • Novo Nordisk$31
  • Mylan Specialty L.p.$27
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$36891%
  • Education$359%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$403 in reported general payments places this provider in the 60th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$33,657
Medicare patients
86
Services billed
346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban109$85,945
JardianceEmpagliflozin56$61,204
OzempicSemaglutide64$59,913
XareltoRivaroxaban58$50,451
TrulicityDulaglutide23$43,901
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$42,335
JanuviaSitagliptin Phosphate21$22,470
TradjentaLinagliptin23$21,263
Breo ElliptaFluticasone/Vilanterol43$19,954
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog34$15,028
Spiriva RespimatTiotropium Bromide24$14,221
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen374$9,744
Celecoxib193$8,468
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,373
Levothyroxine Sodium660$7,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$12$96,687103 claims
PfizerEliquis$51$85,945109 claims
Novo NordiskOzempic, Fiasp$31$63,04675 claims
Johnson & JohnsonXarelto$58$50,45158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,533 family medicine providers in California.

Other family medicine in San Andreas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →